Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoVector, an early-stage therapeutic drug company, has named Paul Steed as its new vice president of R&D.
Subscribe to our email newsletter
Mr Steed has most recently served as head of biology for Serenex, which was acquired in April 2008 by Pfizer.
Albert Bender, CEO of NanoVector, said: “We are delighted to have the opportunity to add someone of Dr Steed’s background to our senior management team.”